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ABSTRACT
Intracranial atherosclerotic stenoses (ICAS) are
one of the most common causes of first and
recurrent cerebrovascular ischaemic events
worldwide, with highest prevalence in Asian,
Hispanic and African populations. Clinical trials
have improved the understanding of epidemi-
ology, risk factors and imaging characteristics of
patients with ICAS. Current therapeutic
approaches concerning these patients include
management of risk factors, best medical ther-
apy, potentially endovascular and rarely surgi-
cal therapy. In our review, we elucidate the
current epidemiology and evidence in evalua-
tion of risk factors and therapeutic options for
providing favourable outcome for patients with
ICAS.
PLAIN LANGUAGE SUMMARY
Calcified vessels in the brain are one of the most
common causes of first or recurrent ischaemic
stroke or transient ischaemic attack worldwide,
with highest occurrence in Asian, Hispanic and
African populations. Clinical trials have
improved the understanding of this particular
disease. Current therapy includes management
of risk factors, best medical therapy, potentially
therapy with a wire and rarely surgical therapy.
In our review, we elucidate current knowledge
and recommendations.
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Key Summary Points
Intracranial atherosclerotic stenoses are
one of the most common causes of first
and recurrent cerebrovascular ischaemic
events worldwide
Artery-to-artery embolism, obstruction of
small penetrating arteries and impaired
washout of emboli in hypoperfused
cerebral tissue with/without poor
collaterals are the most important
cerebrovascular event mechanisms in
these patients
Current therapeutic approaches in these
patients include management of risk
factors, best medical therapy, potentially
endovascular and rarely surgical therapy
Novel, large-scale and high-power
randomised clinical trials investigating
efficacy and safety of best medical therapy
including modern treatment such as
proprotein convertase subtilisin/kexin
type 9 (PSCK9) inhibitors and
endovascular therapy are urgently needed
in these patients
Careful patient selection for endovascular
therapy, related to the underlying
pathophysiological mechanism of
cerebrovascular ischaemic events, as well
as improved endovascular devices could
result in future better outcome
INTRODUCTION
Intracranial atherosclerotic stenoses (ICAS) are
one of the most common causes of cerebrovas-
cular ischaemic events worldwide. ICAS account
for around half of transient ischaemic attacks
(TIAs) and ischaemic strokes in Asian popula-
tions, for up to one-third in Black populations,
15% in Hispanic populations and 5–10% in
Caucasian populations [1–4]. The annual risk of
recurrent cerebrovascular ischaemic events in
patients with ICAS varies from 4% to 40%
according to different studies [5–9]. Risk factors
for ICAS traditionally include arterial hyper-
tension, diabetes mellitus, dyslipidaemia, over-
weight, physical inactivity and smoking. Age
and ethnicity also seem to play an important
role [2, 10].
Despite considerable rates of patients with
ICAS, there are still controversies as to what
extent best medical therapy improves outcome
and decreases rates of recurrent cerebrovascular
ischaemic events, disability and mortality and
which patients might benefit from endovascular
or from surgical therapy. Of note, ICAS is a
heterogeneous disease, causing cerebrovascular
ischaemic events by several pathophysiological
mechanisms [11].
We aimed to present a comprehensive over-
view on pathophysiology, epidemiology, risk
factors and current therapy options of patients
with ICAS by performing a systemic review of
current available data.
METHOD
Eligibility Criteria
Eligible studies included all age and ethnic
patient groups with demographic, clinical, lab-
oratory and imaging information on patients
with asymptomatic or symptomatic ICAS. We
excluded studies on patients with non-
atherosclerotic intracranial stenoses and
patients with extracranial atherosclerotic ste-
noses (ECAS) only, as well as case reports and
case series with less than five patients.
Information Sources
Data for this review was identified via a search
on MEDLINE, PubMed and Scopus. Relevant
articles were determined using the search terms
‘‘ICAS’’, OR ‘‘intracranial atherosclerotic
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stenosis’’ OR ‘‘intracranial stenosis’’ AND/OR
‘‘ischaemic stroke’’ OR ‘‘TIA’’ OR ‘‘transient
ischaemic attack’’. Articles published in English
and German between 1 January 1985 and
31 December 2019 were included.
Study Selection
Citations were assessed against the predeter-
mined inclusion and exclusion criteria by MPK
and MRH. Full-text manuscripts were obtained
for all studies entering the review. Any uncer-
tainties about including a specific manuscript
were resolved by consensus. Reasons for exclu-
sion of publications were mainly lack of specific
data e.g. on precise location of atherosclerosis.
Finally, several randomised, observational, non-
randomised controlled trials regarding patients
with ICAS met the inclusion criteria and are
elucidated in this review.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies per-
formed by any of the authors with human par-
ticipants or animals.
DIAGNOSTIC EVALUATION
Diagnostic evaluation of ICAS include tran-
scranial Doppler (TCD) and colour-coded
duplex (TCCD) sonography, magnetic reso-
nance angiography (MRA), computed tomog-
raphy angiography (CTA) and digital
subtraction angiography (DSA). Although TCD,
TCCD, MRA and CTA are non-invasive, safer
and easier accessible modalities, DSA is still
considered to be the gold standard technique
for assessing ICAS [12].
Since neuroimaging techniques have
become more and more available and advanced,
several studies related to ICAS have been pub-
lished within recent years. However, there are
still far more studies published in the field of
ECAS [13–15].
PATHOPHYSIOLOGY
OF CEREBROVASCULAR ISCHAEMIC
EVENTS RELATED
TO INTRACRANIAL
ATHEROSCLEROTIC STENOSIS
Modern neuroimaging techniques such as dif-
fusion-weighted MR imaging (MRI), perfusion-
weighted CT/MRI, MRA, CTA and high-resolu-
tion vessel wall MRI have provided new insights
into ICAS and into their mechanisms causing
cerebrovascular ischaemic events.
An autopsy study (n = 339 brains with
ischaemic brain infarcts, n = 80 controls with
intracerebral haemorrhages) showed ischaemic
stroke to be associated with greater than 30%
ICAS in 27% vs. less than 30% ICAS in 15.5%
(p\ 0.05). In those where the stenotic plaques
were considered to be the cause of ischaemic
stroke (n = 15/259, 5.8%), because of superim-
posed clot or ulcerated plaques, higher-grade
ICAS was more prevalent (73% vs. 27%;
p\0.0001, in greater than 75% vs. 30–75%
ICAS) [16]. Also, other studies have shown a
correlation of higher-grade ICAS and cere-
brovascular ischaemic events [7, 17, 18].
Artery-to-artery embolism, obstruction of
small penetrating arteries and impaired wash-
out of emboli in hypoperfused cerebral tissue
with/without poor collaterals are the most
important cerebrovascular event mechanisms
in patients with ICAS. Rarer causes are hypo-
perfusion with/without poor collaterals as such
or local vessel occlusion. Recent advances in
neuroimaging technologies allow one to deter-
mine the underlying pathophysiological
mechanism.
Artery-to-artery embolism is caused by a
thrombus carried to the distal territory by rup-
ture of the atherosclerotic plaque causing ICAS
with/without an additional thrombus. Turbu-
lence of blood flow caused by the vessel nar-
rowing, as well as fast velocity increase and
shear stress on the endothelium encourage fis-
suring of the plaque. The latter may rupture and
may lead to activation of platelets and clotting
factors. In the case of an ischaemic stroke
caused by this mechanism, typically, multiple,
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scattered, small infarcts are seen on diffusion-
weighted MRI (DWI) [19].
Obstruction of small penetrating arteries
(Fig. 1) is caused by atherosclerotic plaques
protruding into the orifice of perforators and
thus impairing blood flow. If an ischaemic
stroke is caused by this mechanism, typically,
deep subcortical infarcts are seen on DWI [20].
Intracranial atherosclerotic plaques can be
identified by high-resolution (HR) vessel wall
MRI and by intravascular sonography, which
allow visualization not only of the vessel lumen
but also of the vessel wall. Similar to more
accessible extracranial plaques, intracranial
plaques with thin fibrous caps, large lipid cores,
high macrophage content, high microvessel
density and intraplaque haemorrhage are con-
sidered to be unstable and rupture prone due to
the increased risk of plaque destabilization
[21–30].
Hypoperfusion with/without poor collaterals
may be present in high-grade ICAS. Its typical
infarction shows a border zone location and
pattern [31].
In situ obstruction may possibly show mod-
erate to even large infarcts, especially if the
intracranial internal carotid artery, proximal
middle cerebral artery or vertebrobasilar arteries
are involved leading to an acute large vessel
occlusion. However, compared to patients with
cardiac embolism, infarct size is smaller in
many patients with ICAS because of the well-
developed collateral circulation due to the
chronic nature of the disease [19].
Of note, a combination of more than one
mechanism is also possible [32–34]. For exam-
ple, impaired washout of emboli may occur in
the case of embolism and hypoperfusion with/
without poor collaterals combined [35].
In the WASID (Warfarin-Aspirin Symp-
tomatic Intracranial Disease) trial (Table 1), not
all 70–99% ICAS were haemodynamically rele-
vant and not all 50–69% ICAS were haemody-
namically irrelevant. Collaterals may be seen in
present or regressed high-grade ICAS. Depend-
ing on the overall haemodynamic status, col-
laterals may develop in moderate ICAS as well.
Furthermore, collaterals may indicate the pres-
ence of an emboligenic plaque, with past
emboli having induced collateral flow. Also,
competing antegrade vs. retrograde collateral
flow may cause slower flow at the ICAS location
rendering it more thrombogenic [17].
ASYMPTOMATIC INTRACRANIAL
ATHEROSCLEROTIC STENOSES
Few studies have specifically investigated the
prevalence, risk factors and prognosis of
asymptomatic ICAS, such as the AsIA (Barcelona
Asymptomatic Intracranial Atherosclerosis) and
the Rotterdam study (Table 1) [36, 37].
A post hoc analysis of data from the WASID
trial showed coexisting asymptomatic ICAS in
18.9% (n = 14/74) of patients who underwent
DSA and in 27.3% (n = 65/238) who underwent
MRA. During follow-up, despite the high rate of
coexisting symptomatic ICAS, the risk of recur-
rent ischaemic stroke due to asymptomatic
ICAS was low and only 5 (5.9%, 95% CI
2.1–12.3%) ischaemic strokes occurred in the
asymptomatic ICAS territory (risk at 1 year
3.5%, 95% CI 0.8–9.0%) [40].
Fig. 1 High-resolution flat panel cone beam CT, DSA and MRI of a patient with high-grade ICAS of the basilar artery and
ischaemic stroke predominantly of a perforator-type pattern
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Despite the reported prevalence and impact
of asymptomatic ICAS, the focus of our review is
on symptomatic ICAS.
EPIDEMIOLOGY, RISK FACTORS
AND CURRENT AVAILABLE BEST
MEDICAL THERAPY
Several studies have investigated conventional
risk factors for ICAS, mainly in the Asian pop-
ulations. They are traditionally divided into two
major groups: modifiable (arterial hypertension,
diabetes mellitus, dyslipidaemia, overweight,
physical inactivity, smoking, etc.) and non-
modifiable (age, ethnicity, sex, family history of
vascular disease) [19, 41, 42].
Some studies investigating risk factors for
ICAS have shown differences between ICAS and
ECAS [43].
Better understanding of risk factors tradi-
tionally associated with ICAS may not only
explain the presence of ICAS and ethnic differ-
ences but may also lead to improved outcome
in the case of best medical therapy. The fol-
lowing paragraphs focus on epidemiology and
on recommendations for treatment of most
prevalent modifiable risk factors in patients
with ICAS.
Arterial Hypertension
Arterial hypertension is one of the most
important risk factors for ICAS according to
autopsy as well as according to many clinical
studies [2, 32, 42, 44, 45]. Studies suggest that
Asian and African populations are more prone
to high-volume arterial hypertension due to
more sodium retention, whereas resistant arte-
rial hypertension is more frequent among Cau-
casian populations [46]. Arterial hypertension
has been reported to cause haemodynamic
stress, to accelerate atherosclerosis by injuring
vessel endothelium and increasing its perme-
ability for lipoproteins [47]. Intracranial arteries
are more prone to damage induced by arterial
hypertension than extracranial arteries. This
may be explained by the different architecture
of the vessel walls. Intracranial arteries consist
T
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of a thinner media and adventitia, as well as of
fewer elastic medial fibres than extracranial
arteries [48]. Arterial hypertension has been
demonstrated to be associated with occurrence
of ICAS as such, with ICAS severity and pro-
gression [49].
The WASID trial (Table 1) showed a higher
prevalence of recurrent ischaemic stroke among
patients with arterial hypertension. Two
patients were excluded because of lack of
information about blood pressure. All patients
had blood pressure measured at baseline and at
every 4-month visit. Data revealed the associa-
tion between arterial hypertension defined as at
least 160/90 mmHg vs. at least 140/90 mmHg
and an increased risk of ischaemic stroke not
only in the territory of the stenotic vessel
(p = 0.0065/p\0.0001 vs. p = 0.015/p\0.0001
respectively) but also in other vascular territo-
ries (p\0.0001/p = 0.003 vs. p = 0.0003/
p\0.0001). Furthermore, among patients with
50–70% ICAS, BP of at least 140/90 mmHg was
associated with a greater risk of any ischaemic
stroke (p\ 0.0001, p = 0.003), as well as of
ischaemic stroke in the ICAS territory
(p = 0.0002, p = 0.010), similar to the group at
large. Furthermore, during follow-up, 30.7% of
patients with a mean SBP of at least 140 mmHg
suffered an ischaemic stroke, myocardial
infarction or vascular death, compared to 18.3%
of patients with a mean SBP less than
140 mmHg (p\ 0.0005) [50]. Multivariable
analysis showed that SBP of at least 140 mmHg
(HR 1.79, 95% CI 1.27–2.52; p = 0.0009) was
associated with an increased risk (40%) of a
recurrent ischaemic cardio- or cerebrovascular
event or vascular death [45]. In the WASID trial
(Table 1), elevated mean SBP at enrolment was
also found to be associated with presence vs.
absence of coexisting asymptomatic ICAS
(144.7 mmHg vs. 139.4 mmHg, p = 0.028) [40].
In the TOSS-II (Trial of cilOstazol in Symp-
tomatic intracranial arterial Stenosis II) study
(Table 1), there turned out to be an association
between mean SBP levels and progression of
ICAS. Patients with normal SBP levels (less than
120 mmHg) had lowest rates of progression of
ICAS (21.4%), whereas patients with levels of at
least 160 mmHg showed highest rates of pro-
gression (38.9%) [51, 52].
In the SAMMPRIS (Stenting and Aggressive
Medical Management for Preventing Recurrent
stroke in Intracranial Stenosis) trial (Table 1),
three BP measurements were recorded and
averaged at baseline and at each follow-up visit
throughout the study [53]. The frequency of BP
data collection depended on achievement of
the SBP target. The normal schedule of follow-
up visits was every 4 months after the adjust-
ment of antihypertensive regimen according to
the target SBP. A post hoc analysis of patients
included in the arm of best medical therapy
only found that 53% of these patients had a
mean SBP within target (less than 140 mmHg)
during their participation in the study and that
they were significantly less likely to have a
recurrent ischaemic stroke, myocardial infarc-
tion or vascular death (OR 1.3, 95% CI 1.1–1.7),
compared to those who did not reach those
targets (OR 2.1, 95% CI 1.2–4.0) [54].
In the VERiTAS (Vertebrobasilar flow Evalu-
ation and Risk of Transient ischaemic Attack
and Stroke) study (Table 1), among 10 subse-
quent vertebrobasilar territory strokes, seven
occurred in patients with BP less than
140/90 mmHg compared to three in patients
with BP of at least 140/90 mmHg (p = 0.33).
When subgroups were compared according to
both BP and haemodynamic status, patients
with both low flow and BP less than
140/90 mmHg (n = 10) had the highest risk of
subsequent ischaemic stroke (n = 4, HR 4.5,
95% CI 1.3–16.0; p = 0.02) when compared to
all other subgroups combined. After adjustment
for the previously identified risk factors for
stroke in this cohort, the low flow and BP less
than 140/90 mmHg subgroup remained at sig-
nificantly higher risk (HR 7.3, 95% CI 1.4–37.9;
p = 0.02) [55].
Based on the evidence from large ran-
domised trials (WASID, SAMMPRIS), the Amer-
ican Heart Association (AHA)/American Stroke
Association(ASA) guidelines of 2014 recom-
mend a BP target of less than 140 mmHg for
symptomatic 50% or higher ICAS of a major
intracranial artery (class I; level of evidence B)
[56]. Similarly, the European Society of Cardi-
ology (ESC)/European Atherosclerosis Society
(EAS) 2019 guidelines also recommend a BP
target of less than 140/90 mmHg [57]. However,
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the subgroup of patients with ICAS and low
flow might need higher target levels.
Diabetes Mellitus
Diabetes mellitus has consistently been identi-
fied as an independent risk factor for ICAS
[2, 42, 44, 58, 59]. Diabetes mellitus has been
shown to reduce antioxidant capacity and
increase oxidative stress, leading to endothelial
dysfunction and inflammation [60].
A couple of decades ago, an autopsy study
with consecutive Hong Kong patients (n = 114)
demonstrated a greater than 50% ICAS deter-
mined by morphometric measurement in
autopsy in 31.4% of patients. The incidence of
risk factors (ischaemic heart disease, arterial
hypertension, diabetes mellitus, smoking, his-
tory of stroke) was obtained by reviewing clini-
cal history and interviewing patients’ relatives.
Results showed the association of diabetes
mellitus as well as of arterial hypertension and
age with ICAS [61].
A case–control autopsy study in mostly
white consecutive stroke patients (n = 339)
reported that diabetes mellitus was the only
modifiable risk factor associated not only with
intracranial atherosclerotic plaques but also
with ICAS, defined as a greater than 30% nar-
rowing of the lumen on the surface section of
the arteries [16].
Diabetes mellitus and metabolic syndrome
have been reported to be more important risk
factors for ICAS than for ECAS and non-
atherosclerosis-related stroke (diabetes mellitus:
67% ICAS, 60% ECAS, 48% non-atherosclerotic
stroke, and 23% controls, p\0.05 ICAS vs.
controls; metabolic syndrome: 62% ICAS, 40%
ECAS, 40% non-atherosclerotic stroke, and 35%
controls, p\ 0.05 ICAS vs. controls), according
to the Northern Manhattan Stroke Study. In a
multivariate analysis, diabetes mellitus con-
ferred a higher risk for ischaemic stroke related
to ICAS compared to non-atherosclerotic stroke
(OR 10.8, 95% CI 2.0–57 vs. OR 2.7, 95% CI
1.9–3.9; p\ 0.05) and to ECAS-related stroke
(OR 6.2, 95% CI 1.2–32). The metabolic syn-
drome also proved to be a risk factor for
ischaemic stroke related to ICAS (OR 4.6, 95%
CI 1.1–18.7) when compared to ECAS (OR 2.3,
95% CI 0.6–9.1) and non-atherosclerosis (OR
2.4, 95% CI 1.7–3.3) related stroke [59].
The AsIA study (Table 1) identified diabetes
mellitus (OR 2.95, 95% CI 1.68–5.18; p\ 0.001)
as the most relevant risk factor for asymp-
tomatic ICAS of any degree and also for mod-
erate to severe asymptomatic ICAS (OR 2.85,
95% CI 1.16–6.96; p = 0.02) [37]. Another study
among asymptomatic Chinese patients suffer-
ing from diabetes mellitus with ICAS of one
(n = 185), both (n = 200) or no middle cerebral
artery/arteries (n = 1492) examined patients
with TCD. In 20.6% of patients with type 2
diabetes mellitus there was evidence of ICAS of
the middle cerebral artery on at least one side.
Severity of ICAS and increasing number of ste-
notic vessels were associated with serum glucose
or glycated haemoglobin levels (HbA1c), dura-
tion of diabetes mellitus, as well as with age,
higher SBP and LDL-C levels [62].
In prospective Korean studies, diabetes mel-
litus was found to be an independent risk factor
for ICAS in female patients only after 50 years of
age and to show a relation with ICAS in poste-
rior but not in anterior circulation [32, 63].
The SAMMPRIS and the WASID trials
(Table 1) studied the relationship between bet-
ter diabetes mellitus control and risk of recur-
rent ischaemic stroke or vascular events in the
follow-up periods of both studies. The protocol
of the SAMMPIS trial required testing HbA1c
levels in diabetic patients every 6 months in
patients with glycaemic control in the target
levels and quarterly in patients who were out of
the target levels. A post hoc analysis of patients
(n = 227) included in the best medical therapy
arm of the study failed to demonstrate an
association between better controlled HbA1c
levels (target less than 7.0%) and recurrence of
ischaemic stroke, myocardial infarction and
vascular death of other cause (OR 2.0, 95% CI
0.99–4.1) and with ischaemic stroke (OR 2.3,
95% CI 1.0–5.0) at 3-year follow-up [54]. These
findings are similar to the results of the WASID
trial. In this study, the mean HbA1c level in
diabetic patients was 8.4%. A total of 91% of
enrolled patients were prescribed insulin or an
oral hypoglycaemic agent during follow-up.
However, results showed that poor control of
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diabetes mellitus, defined as HbA1c greater than
7.0%, was not significantly associated with a
higher risk of recurrent ischaemic stroke,
myocardial infarction or vascular death, nor
with recurrent ischaemic stroke alone during
follow-up. The risk of ischaemic stroke,
myocardial infarction or vascular death was
31% in diabetic patients with HbA1c greater
than 7.0% (n = 117) and 20% in diabetic
patients with good HbA1c control (n = 59) [50].
Possible explanations for the failure of the
SAMMPRIS and the WASID trial to detect a
significant benefit of better HbA1c control may
be either a true lack of benefit or a lack of power
to detect an effect.
The benefit of better glucose control not
only in diabetic patients but also in patients
with insulin resistance for lower recurrence of
cardio- and cerebrovascular ischaemic events
has been demonstrated by the IRIS (Insulin
Resistance Intervention after Stroke) trial
(Table 1). The possible explanation for the study
findings is that pioglitazone improves insulin
sensitivity, reduces plasma glucose, reduces
biomarkers of systemic inflammation and
improves vasomotor reactivity. Also, it has
favourable effects on lipid metabolism, blood
pressure and thrombosis. The conclusion drawn
from this study was that pioglitazone was
effective in secondary prevention of recurrent
ischaemic stroke in non-diabetic patients with
insulin resistance. The study did not analyse
ischaemic stroke related to ICAS as such [65].
According to the ESC/EAS 2019 guidelines,
HbA1c less than 7% is recommended for vas-
cular disease prevention [57]. Although the
AHA/ASA 2019 guidelines did not set any
specific target goals for HbA1c and serum glu-
cose for patients with ICAS, they probably
should not differ from those recommended in
(atherosclerotic) vascular disease [66].
Dyslipidaemia
Dyslipidaemia is an important risk factor for
ICAS, more even for ECAS [2, 42, 44, 67–69].
In a prospective multicentre study with
enrolment of 1000 Korean patients with acute
ischaemic stroke or TIA (less than 7 days after
onset), which was caused by either ICAS
(n = 688), ECAS (n = 271) or tandem stenoses
(n = 41), evaluated by CTA, MRA or DSA, dys-
lipidaemia was identified as the only modifiable
risk factor being more prevalent in ECAS (OR
1.50, 95% CI 1.117–2.018, p = 0.007) compared
to ICAS [32].
Accumulation of LDL-cholesterol (C) in the
intima initiates the development and progres-
sion of atherosclerosis and eventually leads to
the formation of a plaque. HDL-C plays an anti-
atherosclerotic role by promoting cholesterol
efflux from macrophages, inhibiting oxidation
of LDL-C and migration of smooth muscle cells
and aggregation of platelets [70]. However,
intracranial arteries seem to have a specific
glycocalyx composition on endothelial cells
that might inhibit the trapping of very low
density lipoprotein resulting in reduction of
fatty depositions [71]. Ethnicity and environ-
mental factors may influence the effect of dys-
lipidaemia on atherogenesis of intracranial
arteries. Generally, compared to Caucasian
populations, Asian and African populations
exhibit lower serum lipid levels, which may be
one factor explaining the lower incidence of
extracranial and coronary atherosclerosis in
these populations [72]. Apolipoprotein (apo)-AI,
the major apolipoprotein in HDL-C, has
antioxidant and anti-inflammatory effects,
whereas apo-B represents the total number of
potentially atherogenic properties, generates
multiple proinflammatory products and aggra-
vates atherogenesis within the vascular wall
through oxidation. Lo´pez-Cancio et al.
demonstrated the association between triglyc-
eride/HDL-C ratio and moderate to severe
asymptomatic 50% or higher ICAS, although it
was not an independent predictor [37]. A posi-
tive correlation between the apo-B/apo-AI ratio
and the presence and severity of ICAS has been
shown, suggesting that the apo-B/apo-AI ratio
may be a promising biomarker for predicting
the risk and severity of ICAS [73].
The WASID trial (Table 1) found mean LDL-
C levels of 3.2 mmol/l and mean HDL-C levels
of 1.1 mmol/l at baseline. Among all patients
enrolled, 61% were on a statin at baseline and
82.4% took a statin at any time during the trial.
Univariate analysis for the association between
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dyslipidaemia and recurrent ischaemic stroke,
myocardial infarction or vascular death
demonstrated that total cholesterol levels of at
least 5.2 mmol/l were associated with an
increased risk of a major recurrent vascular
event (p = 0.0223). Furthermore, 25.0% of
patients with LDL-C levels of at least 3.0 mmol/l
suffered an ischaemic stroke, myocardial
infarction or vascular death, compared to 18.5%
of patients with mean LDL-C levels less than
3.0 mmol/l (p = 0.029) over the same period.
Multivariable analysis showed that total
cholesterol level of at least 5.2 mmol/l (HR 1.44,
1.00–2.07; p = 0.048) was associated with an
increased risk of ischaemic stroke, myocardial
infarction or vascular death during the follow-
up period. Also, the results revealed that
patients were more likely to suffer a recurrent
ischaemic stroke if they had total cholesterol
levels of at least 5.2 mmol/l (HR 2.06,
p = 0.0006), LDL-C levels of at least 2.6 mmol/l
(HR 1.72, p = 0.0326), non-HDL-C levels of at
least 3.4 mmol/l (HR 1.94, p = 0.0109) and a
ratio of total cholesterol/HDL-C levels of at least
4.4 (HR 1.89, p = 0.0043). Furthermore, a total
cholesterol of at least 5.2 mmol/l (HR 1.95, 95%
CI 1.29–2.97; p = 0.002) among patients with
SBP of at least 140 mmHg (HR 1.58, 1.07–2.32;
p = 0.02) was the most important predictor of a
recurrent ischaemic stroke. History of dyslipi-
daemia was independently associated with sev-
ere ICAS (OR 1.62, 95% CI 1.09–2.42; p = 0.02).
Furthermore, patients with ICAS of the basilar
artery were most likely to have dyslipidaemia
(70.86% vs. 64.81% with intracranial ICAS of
the internal carotid artery, 57.71% with ICAS of
the middle cerebral and 63.81% with ICAS of
the vertebral artery; p = 0.054) [45, 74].
The SAMMPRIS trial (Table 1) had LDL-C
levels below 1.8 mmol/l as a primary risk factor
target, as well as non-HDL-C levels below
2.6 mmol/l as a secondary target, with stan-
dardised measurements at baseline, 30 days and
at 4 months, by using a central core lipid labo-
ratory. Among all patients enrolled in the best
medical therapy arm of the trial, a total of 47%
had a mean target of LDL-C levels below
1.8 mmol/l and 60% of non-HDL-C levels below
2.6 mmol/l. According to the post hoc analysis
of the conservatively treated patients, lower
continuous LDL-C and lower non-HDL-C levels
were associated with lower likelihood of recur-
rent ischaemic stroke, myocardial infarction or
vascular death, as well as of recurrent ischaemic
stroke alone until 3-year follow-up [54].
According to the SPARCL (Stroke Prevention
by Aggressive Reduction in Cholesterol Levels)
trial (Table 1), which was not specific to patients
with ICAS, reduction of LDL-C levels below
1.81 mmol/l was associated with a 28% reduc-
tion in risk of ischaemic stroke compared with a
level above 2.59 mmol/l [75]. A post hoc anal-
ysis investigating atorvastatin vs. placebo
showed atorvastatin 80 mg/day to be effective
in reducing recurrence risk of ischaemic stroke
among patients with atherosclerotic large vessel
disease. However, the SPARCL trial was under-
powered for subgroup analyses.
A randomised parallel-group event-driven
study assigned a total of 2860 patients with a
recent (less than 3 months) ischaemic stroke or
a TIA (less than 15 days) to a target LDL-C level
of below 1.8 mmol/l (lower-target group,
n = 1430) or to a target range of 2.3–2.8 mmol/l
(higher-target group, n = 1430) [76]. All patients
enrolled had either ECAS, ICAS, atherosclerotic
plaques of the aortic arch (4 mm or larger) or a
known history of coronary artery disease. The
primary endpoint was defined as ischaemic
stroke, myocardial infarction, new symptoms
leading to urgent coronary or carotid revascu-
larisation or death from vascular causes during
the follow-up period of 3.5 years. Achieved LDL-
C targets of 1.8 mmol/l were related to a lower
risk of major vascular events, compared to
higher LDL-C levels (n = 121, 8.5% in the lower-
target group vs. n = 156, 10.9% in the higher-
target group [HR 0.78 (0.61–0.98), 95% CI,
p = 0.04]).
AHA/ASA 2019 guidelines recommend high-
intensity statin therapy, independent of base-
line LDL-C levels, to reduce the risk of vascular
events for patients up to 75 years of age with
cerebrovascular ischaemic events of atheroscle-
rotic origin and without contraindications.
Also, they recommend moderate intensity sta-
tin therapy for those over 75 years of age or for
those with conditions influencing statin safety
or a history of statin intolerance [66].
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According to the ESC/EAS 2019 guidelines a
therapeutic regimen that achieves at least a 50%
LDL-C reduction and a LDL-C goal of below
1.4 mmol/l, non-HDL-C less than 2.2 mmol/l,
triglycerides less than 1.7 mmol/l and apo-B less
than 0.0013 mmol/l for very high risk patients
is recommended for the management of dys-
lipidaemia. Very high risk patients are defined
as those with documented atherosclerotic car-
diac disease, as well as those after a cerebrovas-
cular event [57].
Although there are no secondary prevention
recommendations about target lipid levels in
patients with ICAS, for patients with an
ischaemic stroke or TIA attributable to 50% or
higher stenosis of a major intracranial artery,
high intensity statin therapy is recommended
(class I; level of evidence B), according to AHA/
ASA 2014 guidelines [56].
Overweight and Physical Inactivity
Obesity, defined as a body mass index (BMI) of
30 kg/m2 or higher is an established risk factor
for stroke [77].
BMI was recorded at every visit in the
SAMMPRIS trial (Table 1). Only 19% of patients
enrolled in the best medical therapy arm of the
study were in the BMI target (from baseline
until adverse event or close-out), defined as BMI
less than 25 kg/m2 for patients with initial BMI
between 25–27 kg/m2 and reduction of body
weight by 10% for patients with initial BMI
greater than 27 kg/m2. Results from the post
hoc analysis demonstrated that control of BMI
did not have a significant effect on the 3-year
rates of ischaemic stroke, myocardial infarction
or vascular death (OR 0.9, 95% CI 0.4–2.0), nor
on the 3-year rate of ischaemic stroke alone (OR
0.9, 95% CI 0.4–2.1) [54].
Physical activity has been proven to be of
benefit, reducing risk factors and risk of stroke
[78].
Physical activity was assessed in the SAMM-
PRIS trial (Table 1) according to the 8-point
Physician-based Assessment and Counseling for
Exercise (PACE) questionnaire, which the par-
ticipants completed at each visit [79]. Moderate
exercise included activities like brisk walking or
slow cycling for at least 10 min at a time,
whereas vigorous exercise consisted of jogging
or fast cycling for at least 20 min at a time.
Walking turned out to be the most common
form of exercise at all time points, as measured
by both the duration of exercise and the num-
ber of patients performing the exercise. The
mean duration of walking and other aerobic
activities increased significantly from baseline
to all other time points. Physical activity out of
target was defined as a PACE score of 3 or less
(3 = trying to do vigorous or moderate exercise
but not exercising regularly, 2 = no vigorous or
moderate exercise but thinking of starting in
next 6 months, and 1 = no vigorous or moder-
ate exercise and no intention to start in next
6 months). Results from the post hoc analysis of
the patients enrolled in the best medical ther-
apy arm only revealed that for the endpoint of
ischaemic stroke alone over the follow-up of
3 years, physical activity was the only risk factor
associated with fewer events (OR 0.5, 95% CI
0.4–0.7). Furthermore, participants who were
reaching the target for physical activity were
significantly less likely to have a recurrent vas-
cular event over the follow-up period compared
to those who did not achieve those targets. The
conclusion was drawn that while arterial
hypertension and dyslipidaemia may contribute
to the risk of recurrent vascular ischaemic
events, the independent effect of physical
activity was stronger for the prediction of vas-
cular events. Notably, physically inactive
patients had up to five times the likelihood of
having an ischaemic stroke, myocardial infarc-
tion or vascular death, as well as a sixfold
increased risk of an ischaemic stroke compared
to physically active patients.
According to AHA/ASA 2014 guidelines all
patients with a cerebrovascular ischaemic event
should be screened for obesity with measure-
ment of BMI (class I; level of evidence C) [56].
Despite the shown beneficial effects of weight
loss on risk factors, the usefulness of weight loss
among patients with a recent cerebrovascular
ischaemic event and obesity is uncertain
(class IIb; level of evidence C). Since the associ-
ation between obesity and increased risk for
ischaemic stroke may be largely explained by
the intermediate risk factors, the consequences
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of obesity are controversial and not well estab-
lished yet.
AHA and ACC recommend that adults par-
ticipate in 3–4 sessions of aerobic physical
activity a week, lasting an average of 40 min and
involving moderate (e.g. brisk walking) or vig-
orous (e.g. jogging) intensity [80].
According to ESC/EAS 2019 guidelines a total
of 3.5–7 h moderately vigorous physical activity
per week or 30–60 min most days is the target
goal for vascular disease prevention [57].
Although there are no secondary prevention
recommendations about physical activity
which are specific to patients with ICAS, these
patients may also benefit from regular exercise,
as mentioned above. However, it should be
taken into consideration that low flow patients
should rather avoid intensive physical activity.
Smoking
Smoking is widely accepted as a major risk fac-
tor, increasing the risk of ischaemic stroke two-
to fourfold. Pathophysiologically it increases
blood pressure, heart rate and oxidative stress
[81].
It has been reported to play an important
role both in patients with ICAS [2] and in those
with ECAS [82]. However, a randomised
prospective study in patients (n = 989) with an
acute ischaemic stroke or TIA and ICAS detected
by MRA concluded that smoking may be more
strongly associated (OR 1.83, 95% CI 1.07–3.16,
p = 0.026) with ICAS (32.9%) than with ECAS
(28.2%) [83]. Smoking has been shown to cor-
relate with ICAS progression and severity
[84, 85].
Although in the SAMMPRIS and WASID tri-
als (Table 1) smoking was recorded at all study
visits, post hoc analyses of both studies failed to
demonstrate the benefit of its control for
reducing the rate of recurrent vascular events.
According to AHA/ASA 2014 guidelines,
smokers with a cerebrovascular event should
receive in-hospital initiation of high-intensity
behavioural interventions to promote smoking
cessation and for smokers with an acute
ischaemic stroke, nicotine replacement therapy
is recommended (class IA; level of evidence A).
Furthermore, healthcare providers should
strongly advise every patient who smokes to
quit (class I; level of evidence C-EO) [66].
Although there are no secondary prevention
recommendations about smoking which are
specific to patients with ICAS, smoking cessa-
tion should be aimed for.
Healthy Lifestyle
Lifestyle modification is crucial for achievement
of risk factors targets in patients with ICAS.
SAMMPRIS was the first trial (Table 1) which
provided a commercially available telephonic
lifestyle modification program (INTERxVENT)
free of charge for all patients during study par-
ticipation. Lifestyle coaches provided individu-
alised risk factor advice twice a month for
6 months and monthly thereafter during the
follow-up period. Patients were divided into
compliant patients (n = 201), who had at least
78.5% of calls and into noncompliant patients
with less than 78.5% of calls (n = 200). There
was a significant difference between compliant
vs. noncompliant patients in the change in
HbA1c from baseline to 6 months
(- 0.7% ± 1.9%, n = 59 vs. 0.2% ± 2.7%,
n = 58; p = 0.04) and in the change in SBP from
baseline to 24 months (- 18.4 ± 21.6 mmHg,
n = 171 vs. - 11.2 ± 23.5 mmHg, n = 130;
p = 0.006). They also differed in the change
from baseline to 36 months (0.3 ± 0.4 mmol/l,
n = 55 vs. 0.1 ± 0.3 mmol/l, n = 17; p = 0.03)
for HDL-C levels. However, there was no dif-
ference for BMI [86]. These results demonstrate
that healthy lifestyle leads to better control of
several risk factors.
Healthy living, including healthy diet and
regular physical activity, has also been recom-
mended by AHA/ASA 2019 guidelines for all
patients after an acute ischaemic stroke [66].
Patients with ICAS should also aim at a
healthier lifestyle as part of secondary
prevention.
Age, Ethnicity and Genetics
Results of the AsIA study (Table 1) identified age
(OR 1.05, 95% CI 1.004–1.1; p = 0.03) to be
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associated with moderate to severe asymp-
tomatic ICAS [37].
There is controversial data on studies on the
prevalence of ICAS in patients at different age.
Autopsy and imaging studies have found that
ICAS is more prevalent later in life than ECAS
[16, 32]. One of the potential explanations is
related to the greater antioxidant enzyme
activity at younger age in intracranial arteries,
making them more resistant to atherosclerotic
plaques [87].
Potential reasons for ethnic differences in
the prevalence, severity and location, but also
in the pathogenesis and prognosis of ICAS may
partially be explained by differences in risk
factor profiles [88]. For instance, higher rates of
obesity and hyperglycaemia as well as lower
rates of physical activity are more typical for
Hispanic rather than for Caucasian populations
[89]. Also, studies demonstrated Asian popula-
tions to have a higher prevalence of arterial
hypertension, smoking and visceral obesity,
associated with insulin resistance [90, 91].
Also, polymorphisms such as for adipocy-
tokines, lipoprotein lipase and C-reactive pro-
tein have been described to be present in
patients with ICAS but also ECAS [92].
Moreover, the ring finger protein 213
(RNF213) has been shown to be a susceptibility
gene not only for moyamoya disease but also for
ICAS. In a meta-analysis (11 studies, 1778
patients with ICAS), the variant RNF213
p.R4810K has been found to increase the risk of
ICAS in Chinese patients (OR 5.59, 95% CI
2.12–14.75; p = 0.001), with significantly lower
effect size than in Japanese and Korean patients
(OR 10.71 and 28.52, 95% CI 3.97–28.91 and
11.04–73.67, respectively). The variant RNF213
p.R4810K is absent in non-Asian populations.
Other variants of RNF213 have been identified
to be associated with ICAS [93].
Anticoagulation and Antithrombotics
Blood thinning is of crucial importance in
therapy of patients with ICAS. Anticoagulation
interferes with the coagulation cascade, and
antithrombotics interfere with platelet activa-
tion and aggregation.
Anticoagulants have empirically been used
for patients with severe occlusive disease in the
vertebrobasilar arteries and in recurrent ischae-
mic stroke according to favourable results of
clinical trials several decades ago [94].
However, the WASID trial (Table 1) showed a
benefit of antiplatelet treatment over anticoag-
ulation in patients with non-disabling ischae-
mic stroke or TIA within 90 days before
randomisation, attributable to 50–99% ICAS.
This occurred even though the dosage of aspirin
was considerable (1300 mg/day). This high
dosage of aspirin was prescribed because of its
supposed better ability to decrease platelet
resistance [95, 96], to diminish shear-induced
platelet aggregation [97] and to decrease the
inflammatory component of atherothrombosis
[98–101].
Since non-vitamin K antagonist oral antico-
agulants (NOACs) have been shown to be safer
than vitamin K antagonists (warfarin) in sec-
ondary stroke prevention [102–105], the ques-
tion arises whether NOACs would be effective
and safe in patients with ICAS. There is a need
for clinical trials addressing NOACs in this
specific patient group.
The CLAIR (Clopidogrel plus Aspirin for
Infarction Reduction) study (Table 1) investi-
gated dual antiplatelet therapy for reduction of
microembolic signals (MES) detected by TCD
[106]. MES have been described to be a surrogate
marker for higher risk of cerebrovascular
ischaemic events. All patients had at least 50%
symptomatic ECAS or ICAS of the internal car-
otid artery or ICAS of the middle cerebral artery.
Results from this study indicate that dual anti-
platelet therapy for 7 days is more effective with
a comparable safety than aspirin alone for
reducing the number of MES in acute stroke or
TIA patients with ICAS, which might be related
to a decreased risk of cerebrovascular ischaemic
events.
A substudy of the CHANCE (Clopidogrel in
High-risk patients with Acute Nondisabling
Cerebrovascular Events) trial (Table 1) analysed
the efficacy of dual antiplatelet therapy among
symptomatic patients with ICAS, compared to
patients without ICAS. Results indicated higher
rates of recurrent ischaemic or haemorrhagic
stroke in minor ischaemic stroke or high-risk
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TIA patients with ICAS than in those without.
However, there was no significant difference in
the response to and concerning safety of the
two antiplatelet regimes between patients with
and without ICAS [107, 108].
The GESICA (Groupe d’Etude des Ste´noses
Intra-Craˆniennes Athe´romateuses symptoma-
tiques) trial (Table 1) evaluated the benefit of
medical therapy in patients with minor ischae-
mic stroke or TIA within 6 months and related
to at least 50% ICAS [7]. Patients were treated
with a single antiplatelet agent, with one anti-
platelet and one anticoagulant, with one anti-
coagulant or with other antithrombotic
combinations of antithrombotics and antico-
agulants. There was a considerable recurrence
rate of ischaemic stroke in the territory of the
ICAS but also of other vascular events. Also, the
study found an association between ICAS and
coronary artery and peripheral arterial disease.
Among 20 patients who underwent angioplasty
there was one fatal haemorrhagic stroke, which
occurred 2 months after the procedure.
In the SAMMPRIS trial (Table 1), including
patients with non-disabling ischaemic stroke or
TIA caused by 70–99% ICAS, lower rates of any
stroke or death was found in the best medical
therapy group compared to the percutaneous
transluminal angioplasty and stenting (PTAS)
group.
The VISSIT (Vitesse Intracranial Stent Study
for Ischaemic stroke Therapy) study (Table 1)
also supported the benefit of best medical
therapy within 30 days in patients with symp-
tomatic 70% or higher ICAS [109].
Cilostazol is an alternative antiplatelet hav-
ing been investigated in patients with ICAS. It is
a phosphodiesterase 3 inhibitor with vasodilat-
ing, anti-inflammatory, anti-atherogenic effects
and a low bleeding risk. The TOSS I (Trial of
cilOstazol in Symptomatic intracranial arterial
Stenosis) study (Table 1) randomised Korean
patients with symptomatic ICAS either to
cilostazol (100 mg twice daily) or placebo. All
participants received aspirin 100 mg/day addi-
tionally [110]. Results demonstrated that
cilostazol may not only prevent ICAS progres-
sion, but may even potentiate regression of
ICAS. Furthermore, no ischaemic or
haemorrhagic stroke or TIA occurred in both
groups during the study period of 6 months.
However, the TOSS II study (Table 1) failed to
find a benefit of cilostazol (100 mg twice daily)
and of aspirin (75–150 mg once daily) over
clopidogrel (75 mg once daily) and aspirin
(75–150 mg once daily) in preventing progres-
sion of ICAS and occurrence of new ischaemic
lesions in the territory of ICAS in the follow-up
MRI at 7 months [52]. Safety assessment
revealed that major haemorrhagic complica-
tions were not significantly different between
both groups.
Although both TOSS I and II studies have
limitations including evaluation of radiological
markers only but not of clinical events, Korean
ethnicity of all included patients, short follow-
up periods and small number of enrolled
patients, cilostazol is currently widely pre-
scribed in patients with ICAS, mostly in Asia.
Ticagrelor is another antiplatelet acting as a
platelet P2Y12 receptor antagonist which has
been studied among patients with non-car-
dioembolic minor ischaemic stroke or TIA in
the SOCRATES (Acute Stroke Or Transient
isChaemic attack tReated with Aspirin or Tica-
grelor and patient outcomES) study [111].
Patients were randomised to receive either
ticagrelor (180 mg loading dosage on day 1 fol-
lowed by 90 mg twice daily for 90 days) or
aspirin (300 mg on day 1 followed by
100 mg/day for 90 days). Although the trial
failed to show superiority of ticagrelor over
aspirin, it has been suggested e.g. to be pre-
scribed in carriers of loss-of-function alleles,
causing potential resistance to clopidogrel or in
patients with recurrent cerebrovascular ischae-
mic events.
A substudy of SOCRATES (n = 3081) (Table 1)
has focused on ischaemic strokes caused by
ipsilateral atherosclerotic disease. In this sub-
study, ticagrelor was superior to aspirin in pre-
venting recurrent ischaemic or haemorrhagic
stroke, myocardial infarction or death at
90 days in patients with acute ischaemic stroke
or transient ischaemic attack when associated
with ipsilateral ICAS. There were no significant
differences in the proportion of life-threaten-
ing, major or minor haemorrhages between
both groups [112].
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Prasugrel, which is another antiplatelet and
platelet P2Y12 receptor antagonist, has been
compared to clopidogrel among Japanese
patients with non-cardioembolic ischaemic
stroke (within up to 1–26 weeks before inclu-
sion) in the PRASTRO-I (PRAsugrel and clopi-
dogrel in Japanese patients with ischemic
STROke) study (Table 1) [113]. Patients were
randomly assigned to either prasugrel
(3.75 mg/day) or clopidogrel (75 mg/day) orally.
This study did not confirm non-inferiority of
prasugrel compared to clopidogrel for the pre-
vention of ischaemic stroke, myocardial infarc-
tion and death from other vascular causes in
Japanese patients with non-cardioembolic
stroke. No safety concerns were identified.
Although a total of 29% of enrolled patients had
large artery atherosclerosis, the specific location
was not described in this study.
According to AHA/ASA 2019 guidelines, for
patients with non-cardioembolic acute ischae-
mic stroke the use of antithrombotics rather
than oral anticoagulation is recommended to
reduce risk of vascular events (class I; level of
evidence A) [66].
According to AHA/ASA 2014 guidelines, for
patients with an ischaemic stroke or TIA asso-
ciated with at least 50% ICAS of a major
intracranial artery, aspirin 325 mg/day is rec-
ommended in secondary prevention in prefer-
ence to warfarin (class I; level of evidence B). In
at least 70% ICAS, the AHA/ASA 2014 guidelines
state that the addition of clopidogrel 75 mg/day
to aspirin 100 mg/day for 90 days might be
reasonable (class IIb; level of evidence B) [56].
According to AHA/ASA 2014 guidelines for
patients with ischaemic stroke or TIA
attributable to a 50% or higher ICAS of a major
intracranial artery, the data are insufficient to
make a recommendation in secondary stroke
prevention regarding the usefulness of clopi-
dogrel alone, the combination of aspirin and
dipyridamole or cilostazol alone (class IIb; level
of evidence C) [56].
ENDOVASCULAR THERAPY
The question arises whether endovascular ther-
apy is safe and effective in patients with ICAS
since considerable recurrence rates of cere-
brovascular ischaemic events have been repor-
ted despite best medical therapy [114].
The small calibres of cerebral arteries, the
relative paucity of supporting medial and
adventitia layers, the presence of end-anasto-
mosing perforator branches and the vascular
tortuosity demand specialized interventional
skills and devices [11]. As a result of the diverse
stroke mechanisms of ICAS, careful patient
selection, according to the underlying patho-
physiological pattern, and evaluation of the
indications and procedural risks and benefits are
crucial prior to deciding on endovascular pro-
cedure. The treatment indications will likely
develop in parallel with future advancement of
endovascular techniques and better under-
standing of ICAS.
Various endovascular therapy strategies have
been applied in patients with ICAS in recent
years. The first and most simple endovascular
therapy initiated was the balloon angioplasty
alone. It dilated the calibre of the ICAS, leading
to increase of perfusion in the downstream ter-
ritory. In 1980, two patients with frequent,
severe, progressive symptoms despite anticoag-
ulation and high-grade ICAS of the basilar
artery got treated by cerebral transluminal bal-
loon catheter dilatation [115]. The excellent
angiographic and short-term clinical results in
these two patients as well as the prevalence of
ICAS favoured further research of this approach.
Unfortunately, arterial dissection with consec-
utive thrombosis or rupture, residual stenosis
due to sequestration or vessel recoiling and
acute or subacute vascular occlusion due to the
formation of a wall haematoma were reported
as frequent complications in the next case series
[116].
In order to reduce periprocedural complica-
tions of angioplasty alone, the rigid coronary
Palmaz-Schatz stent was applied for the first
time in 1996 in a patient with recurrent TIA due
to severe ICAS of the right carotid artery despite
antiplatelet and anticoagulant therapy [117].
Deploying the stent led to a better angiographic
result compared to angioplasty alone. The
patient was asymptomatic 4 months after the
procedure. However, probably as a result of the
rigidness of the coronary stent a high rate of up
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to 30% procedure-related complications has
been described in various case series [118].
In a retrospective single-centre trial in
patients (n = 120) with ischaemic stroke or TIA
attributable to 50% or higher ICAS measured by
DSA, primary angioplasty was associated with a
combined periprocedural ischaemic stroke and
death rate of 5.8%. In the mean follow-up per-
iod of 42.3 months there were 6 (3.2%) patients
with an ischaemic stroke in the territory of
treatment and 5 (4.4%) patients with ischaemic
stroke outside the territory of the treated ste-
notic vessel [119].
In 2004, the SSYLVIA (Stenting of SYmp-
tomatic Atherosclerotic Lesions in the Vertebral
or Intracranial Arteries) trial (Table 1) was the
first multicentre, non-randomised, prospective
study using the balloon-expandable Neurolink
stent system (Guidant, Indianapolis, IN, USA) in
patients with symptomatic 50% or higher ICAS
(70.5%) or ECAS (29.5%) [120]. The study
showed that the Neurolink stent system was
associated with a high rate of successful stent
deployment.
Thereafter, in 2005 the first self-expanding,
nitinol-composed Wingspan stent (Boston Sci-
entific, Fremont, CA, USA) was approved by the
US Food and Drug Administration (FDA) for
patients with 50% or higher ICAS, symptomatic
despite medical therapy.
The first randomised trial assessing best
medical therapy with/without the Wingspan
stent system in patients with non-disabling
ischaemic stroke or TIA caused by 70–99% ICAS
is the SAMMPRIS trial (Table 1) [53, 121]. Best
medical therapy was superior to PTAS with the
use of the Wingspan stent system, both because
the risk of any early stroke after PTAS was high
and because the risk of any stroke with best
Fig. 2 MRI of a patient with high-grade ICAS of the middle cerebral artery on the left side causing hypoperfusion
downstream and recurrent ischaemic stroke despite best medical therapy
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medical therapy alone was lower than expected
[122].
Major criticisms about the SAMMPRIS trial
were as follows: experience of interventionalists
was not optimal. Also, 35.3% of patients inclu-
ded in the PTAS group of the SAMMPRIS trial
had not previously failed antithrombotic ther-
apy, which was contrary to the FDA criteria
(deployment of the self-expanding Wingspan
stent only in patients having suffered at least
two ischaemic strokes, attributable to 50% or
higher ICAS, while receiving antithrombotic
therapy) [122]. Patients with only one ischaemic
lesion attributable to 70% or lower ICAS and
without MES detected on TCCD may benefit
from the maximal-dosage dual antiplatelet
therapy, intensive risk factor control and rigor-
ous lifestyle management, including control of
Fig. 3 DSA of a patient with ICAS-related acute large
vessel occlusion of the middle cerebral artery on the left
side and prompt reocclusion after initial reperfusion, then
undergoing intra-arterial infusion of glycoprotein IIb/IIIa
inhibitor and permanent deployment of a stent retriever
with angioplasty
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BMI, smoking cessation and regular physical
activity. However, patients with generalized
atherosclerotic disease, 70% or higher ICAS,
who had recurrent cerebrovascular ischaemic
events due to underlying hypoperfusion with/
without poor collaterals may benefit more from
endovascular therapy. However, the SAMMPRIS
trial did not show a benefit in the subgroup of
patients with cerebrovascular ischaemic events
with underlying hypoperfusion with/without
poor collaterals [123, 124]. But, the small sam-
ple size of this subgroup analysis limits this
finding.
Most patients in the PTAS group were treated
in the acute or subacute stage with median time
from the qualifying event to randomisation of
7 days (interquartile range 4–16 days). In this
time period, atherosclerotic plaques of ICAS
might show a certain instability. These patients
might benefit from endovascular therapy since
their plaques might not stabilize with best
medical therapy alone and cause recurrent
artery-to-artery embolic strokes. Also, unsta-
ble plaques might be dislodged into the orifice
of perforators in endovascular therapy
[125, 126]. Besides, stents might occlude orifices
of perforators by themselves.
Furthermore, among 224 patients in the
PTAS group of the SAMMPRIS trial, 61.2% had
lesions in the anterior circulation and the
remaining (38.8%) in the posterior circulation.
Data from a systematic review including 31
studies and 1177 symptomatic patients with at
least 70% ICAS receiving stenting demonstrated
a significantly lower rate of occurrence of any
stroke or death in the anterior circulation
compared to the rate in posterior circulation
ICAS (6.6 vs. 12.1%, 95% CI 1.21–3.10;
p = 0.006). The small diameter and angulation
of the vertebrobasilar arteries, which is associ-
ated with a higher degree of technical com-
plexity, might have contributed to the
increased periprocedural complication rates
observed in posterior circulation. Furthermore,
the probability that a stent covers the ostia of
perforators and thereby leads to a subsequent
ischaemic stroke is higher in posterior circula-
tion than in anterior circulation [127].
So, it might be of importance to take the
initial composition of ICAS and the precise
underlying cerebrovascular ischaemic event
mechanism into consideration. Also, high pro-
fessional expertise of interventionalists and
application of different endovascular proce-
dures and different stents deployed might
facilitate beneficial outcomes [11].
Similar results as in SAMMPRIS have been
demonstrated by the VISSIT (Vitesse Intracra-
nial Stent Study for Ischaemic Stroke Therapy)
study (Table 1), which included patients with
symptomatic 70–99% ICAS and compared bal-
loon-expandable stenting with the Pharos stent
system plus best medical therapy and best
medical therapy alone [109]. In this study, the
use of a balloon-expandable stent compared
with best medical therapy resulted in an
increased 12-month risk of ischaemic stroke or
TIA in the same territory, and increased 30-day
risk of any stroke or TIA. These findings did not
support the use of a balloon-expandable stent
for patients with symptomatic ICAS.
Criticisms about the VISSIT trial were quite
similar as in the SAMMPRIS trial. In particular
the heterogeneity of included patients and the
non-optimal experience of interventionalists
are comparable.
Regarding atherosclerotic stenosis of verte-
bral arteries, the VIST (Vertebral artery Ischae-
mia Stenting Trial) trial compared vertebral
angioplasty and stenting (balloon-expandable
or self-expandable stent) with best medical
therapy in patients with symptomatic 50% or
higher ECAS (mostly affecting the V1 segment)
in 83% of patients and at least 50% ICAS in 17%
of patients [128]. The study demonstrated safety
of stenting for ECAS.
Low periprocedural risk in stenting of 50% or
higher vertebral ECAS/ICAS has been revealed
in VAST (Vertebral Artery Stenting Trial)
(Table 1). Patients were randomised to stenting
(with choice of stent at the discretion of the
interventionalist) or PTA alone if stent place-
ment turned out not to be feasible or con-
traindicated after the beginning of the
intervention) plus best medical therapy and
best medical therapy alone. There were 16% of
patients with ICAS in the stenting group and
17% in the best medical therapy group.
Endovascular therapy in this study was associ-
ated with a major periprocedural vascular
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complication in about one in 20 patients. In the
patients studied, the risk of any recurrent stroke
under best medical treatment alone was low. It
should be pointed out that more than 80% of
patients included in the study had ECAS [129].
The WEAVE (Wingspan stEnt system
postmArket surVEillance) trial (Table 1), which
enrolled patients with 70–99% ICAS, baseline
mRS score 3 or less, at least two ischaemic
strokes (at least one of which while on best
medical therapy) in the vascular territory of the
ICAS and stenting of the ICAS at least 8 days
after last ischaemic stroke, is the largest up to
date on-label trial for the self-expandable
Wingspan stent system in patients with ICAS
[130]. Results demonstrated safety of the
Wingspan stent system. The rate of any stroke
or death was lower than the target of 4%
periprocedural safety set by the FDA. Since the
design of the Wingspan stent has not substan-
tially changed since its introduction into the
market in 2005, the results of the WEAVE study
have been explained by good experience of
interventionalists as well as by favourable
selection of patients meeting the criteria for
stenting by strictly following the on-label
indications.
CASSISS (China Angioplasty and Stenting for
Symptomatic Intracranial Severe Stenosis) is an
ongoing study (Table 1), which aimed to enrol
380 patients with recent ischaemic stroke or TIA
caused by 70–99% ICAS of a major intracranial
vessel [131]. The recruitment was complete in
November 2017. The study compares best
medical therapy with/without stenting using
the Wingspan stent system. It is noteworthy
that patients recruited in the CASSISS trial suf-
fered their last ischaemic stroke after more than
3 weeks in order to lower periprocedural risk of
stenting. Also, patients with perforator stroke
without distal hypoperfusion with/without
poor collaterals or artery-to-artery embolism
according to MRI were excluded from the study.
Length of ICAS, procedural arterial access
and diameter of culprit arteries and proximity
of the plaque and lenticulostriate perforators
should also be considered before deciding on
the most accurate type of endovascular therapy.
According to the Mori classification, three dif-
ferent types of stenoses are subclassified:
Mori A—a short and concentric lesion with a
short length (less than 5 mm); Mori B—a tubu-
lar or extreme eccentric lesion, at most
3 months old, with intermediate length (be-
tween 5 and 10 mm) and Mori C—a diffuse
lesion, at least 3 months old, with a long length
greater than 10 mm and angled more than 90
[132]. Regarding these lesion characteristics
balloon-mounted stents may be more suit-
able for patients with smooth arterial access and
Mori A ICAS, midbasilar artery ICAS and ICAS of
the distal M1 segment of the middle cerebral
artery; self-expanding stents for patients with
tortuous arterial access and Mori B or C ICAS
and balloon angioplasty alone for patients with
tortuous arterial access with Mori A ICAS and a
small target-vessel diameter of less than 2.5 mm
[133].
According to AHA/ASA 2014 guidelines, for
patients with an ischaemic stroke or TIA
attributable to 70–99% ICAS of a major
intracranial artery, stenting with the Wingspan
stent system is not recommended as an initial
treatment, even for patients who were taking an
antithrombotic agent at the time of ischaemic
stroke or TIA (class III; level of evidence B).
Furthermore, even for patients with 70–99%
ICAS of a major intracranial artery and actively
progressing symptoms after institution of
aspirin and clopidogrel therapy, the usefulness
of angioplasty alone or placement of a Wing-
span stent or other stents is unknown and still
considered investigational (class IIb; level of
evidence C) [56].
At present, we suggest that endovascular
therapy may be considered as a treatment
option for patients with recurrent ischaemic
stroke (Fig. 2) despite best medical therapy and
especially if pathophysiologically attributed to
hypoperfusion with/without bad collaterals.
The most appropriate type of endovascular
therapy should be performed for every patient
individually according to the underlying
pathophysiological cerebrovascular ischaemic
event mechanism and according to character-
istics of ICAS. In future, better experience of
interventionalists and improved features of
stents deployed are also expected to boost out-
come of endovascular therapy in ICAS. The
stent of the future should be more flexible and
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easier to manoeuvre, and the microwire and
guiding catheters should be appropriate to
support the delivery of the stent system. Drug-
eluting stents or PTA balloons may be deployed
to decrease the rate of persisting ICAS and
restenosis.
Another question arises whether endovascu-
lar therapy is safe and effective in patients with
ICAS-related acute large vessel occlusion. Cur-
rently, temporary stent retriever thrombectomy
(SRT) and contact aspiration thrombectomy
(CAT) are the most frequently applied
endovascular therapy strategies in this setting.
Several studies have demonstrated comparable
efficacy. However, evidence is limited since
most data are from small retrospective case
series. For successful CAT, an optimal contact
with the proximal surface of a thrombus is
crucial. However, this contact may be limited in
patients with ICAS since ICAS tend to show an
irregular shape. A stent retriever touches the full
thrombus length and shows a temporary
restoration of flow facilitating endogenous
thrombolysis. Since large vessel occlusion in
ICAS is typically caused by in situ obstruction
based on an unstable plaque, there remains a
high risk of reocclusion by subsequent platelet
activation and thrombus formation. However,
an open artery is crucial for improving out-
come. Rescue therapy may be discussed after
reocclusion. Rescue therapy at present includes
switching to another tool (SRT to CAT or vice
versa), simultaneous use of both SRT and CAT,
infusion of intra-arterial thrombolytics, of intra-
arterial or intravenous glycoprotein IIb/IIIa
inhibitor and transiently or permanently
deploying a stent or a stent retriever with or
without angioplasty (Fig. 3). Repeated passages
of a microwire, a microcatheter and SRT may
further damage the unstable plaque and thus
provoke more platelet activation or dissec-
tion. Intracranial angioplasty with or without
permanently deploying a stent retriever bears
the risk of occlusion of perforators, vessel
injury, resulting in vasospasm, dissection and
reocclusion. Infusion of thrombolytics or gly-
coprotein IIb/IIIa inhibitor elevates the risk of
intracranial haemorrhage. Future studies are
needed concerning endovascular first-line and
rescue therapy in patients with ICAS-related
acute large vessel occlusion [134–137].
SURGICAL THERAPY
Another therapy option to be discussed in
patients with ICAS is surgical therapy. Its
effectiveness and safety remain unclear. Reper-
fusion distal to ICAS can be achieved through
various bypass surgeries using different donors,
recipient arteries and conduit vessels [138].
The landmark international randomised EC-
IC bypass trial performed in 1977 failed to
demonstrate improved outcome after direct
bypass versus best medical therapy among
patients with recent ischaemic stroke, retinal
infarction or TIA attributable to symptomatic
extracranial carotid occlusion, distal carotid
occlusive disease or ICAS of the middle cerebral
artery who were randomly assigned to either
best medical therapy (aspirin 1300 mg/day
usually divided in four dosages) or to the same
regimen with the addition of bypass surgery
consisting of joining the superficial temporal
artery and the middle cerebral artery. Overall,
the study findings did not support surgical
therapy in patients with ICAS on a regular basis,
especially not in patients with at least 70% ICAS
of the middle cerebral artery. One of the major
criticisms that has been raised against the study
was the lack of information about haemody-
namic status of patients, which were enrolled
on the basis of clinical symptoms and angio-
graphic findings only [139–141].
A recent prospective study (n = 112) com-
pared EC-IC bypass with/without best medical
therapy in patients with symptomatic steno-
occlusive disease of the intracranial internal
carotid artery or middle cerebral artery. Best
medical therapy consisted of adequate control
of diabetes mellitus (target HbA1c less than 7%),
blood pressure (below 140/90 mmHg), LDL-C
(less than 2.6 mmol/l) and single antiplatelet
therapy (either aspirin 100 mg/day or clopido-
grel 75 mg/day). Patients were selected using
TCD sonography and cerebral vasodilatory
(CVR) assessment using breath-holding index
(BHI). Patients with impaired BHI (less than
0.69) were further evaluated with
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acetazolamide-challenge technetium-99m hex-
amethylpropyleneamine oxime (99mTc
HMPAO) SPECT. Bypass surgery was offered to
patients with impaired CVR on SPECT. Until
34 months, 13% vs. 45% in the surgery vs. in
the best medical therapy group developed
cerebrovascular ischaemic events. The best
medical therapy was, however, suboptimal,
lacking a lifestyle modification programme, best
lipid-lowering as well as double antithrombotic
therapy with aspirin and clopidogrel during the
first 90 days after the index event [142].
According to AHA/ASA 2019 guidelines EC/
IC bypass has largely been abandoned as a
standard therapy for symptomatic ICAS. How-
ever, surgical revascularisation may be consid-
ered as a treatment option for patients with
recurrent ischaemic stroke despite best medical
therapy and pathophysiologically attributed to
hypoperfusion with/without bad collaterals,
especially if the vascular anatomy is unfavour-
able for endovascular therapy [66].
CONCLUSION
Although understanding of ICAS has improved
significantly in recent years, further research is
warranted for these patients. First, high-quality
imaging techniques could further improve
diagnostics and assessment of intracranial
atherosclerotic plaques. Second, novel, large-
scale and high-power randomised clinical trials
investigating efficacy and safety of best medical
therapy including modern treatment such as
proprotein convertase subtilisin/kexin type 9
(PSCK9) inhibitors and endovascular therapy
are urgently needed. Importantly, careful
patient selection for endovascular therapy,
related to the underlying pathophysiological
mechanism of cerebrovascular ischaemic
events, as well as improved endovascular devi-
ces could result in better prognosis and out-
come. Finally, more attention should be paid to
screening and identification of patients with so
far asymptomatic ICAS in order to prevent
subsequent vascular events.
ACKNOWLEDGEMENTS
Funding. This research received no specific
grant from any funding agency in the public,
commercial or not-for-profit sectors.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Disclosures. Marina Krasteva has received a
personal fee for a stroke research fellowship
from the Konstantin and Zenovia Katzarovi
foundation. Kui Kai Lau has received research
sponsorship from Boehringer Ingelheim, Pfizer,
Sanofi and Eisai. He has served on the Advisory
Board of Boehringer Ingelheim in 2019. Pas-
quale Mordasini and Anderson Chun On Tsang
have nothing to disclose. Mirjam R. Heldner has
served on the Advisory Board of Amgen in 2017
and in 2019.
Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
Open Access. This article is licensed under a
Creative Commons Attribution-Non-
Commercial 4.0 International License, which
permits any non-commercial use, sharing,
adaptation, distribution and reproduction in
any medium or format, as long as you give
appropriate credit to the original author(s) and
the source, provide a link to the Creative
Commons licence, and indicate if changes were
made. The images or other third party material
in this article are included in the article’s
Creative Commons licence, unless indicated
otherwise in a credit line to the material. If
material is not included in the article’s Creative
Commons licence and your intended use is not
permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permis-
sion directly from the copyright holder.To view
Adv Ther
a copy of this licence, visit http://
creativecommons.org/licenses/by-nc/4.0/.
REFERENCES
1. Wong LK. Global burden of intracranial
atherosclerosis. Int J Stroke. 2006;1:158–9.
2. Qureshi AI, Caplan LR. Intracranial atherosclerosis.
Lancet. 2014;383:984–99.
3. White H, Boden-Albala B, Wang C, et al. Ischemic
stroke subtype incidence among whites, blacks, and
Hispanics: the Northern Manhattan Study. Circu-
lation. 2005;111:1327–31.
4. Sacco RL, Kargman DE, Gu Q, Zamanillo MC.
Race–ethnicity and determinants of intracranial
atherosclerotic cerebral infarction. The Northern
Manhattan Stroke Study. Stroke. 1995;26:14–20.
5. Kasner SE, Chimowitz MI, Lynn MJ, et al. Predictors
of ischaemic stroke in the territory of a symp-
tomatic intracranial arterial stenosis. Circulation.
2006;113:555–63.
6. Kern R, Steinke W, Daffertshofer M, Prager R, Hen-
nerici M. Stroke recurrences in patients with
symptomatic vs asymptomatic middle cerebral
artery disease. Neurology. 2005;65:859–64.
7. Mazighi M, Tanasescu R, Ducrocq X, et al.
Prospective study of symptomatic atherothrom-
botic intracranial stenosis: the GESICA study. Neu-
rology. 2006;66:1187–91.
8. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al.
Comparison of warfarin and aspirin for symp-
tomatic intracranial arterial stenosis. N Engl J Med.
2005;352:1305–16.
9. Jung JM, Kang DW, Yu KH, et al. Predictors of
recurrent stroke in patients with symptomatic
intracranial arterial stenosis. Stroke. 2012;43(10):
2785–7.
10. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt
B. Race and sex differences in the distribution of
cerebral atherosclerosis. Stroke. 1996;27(11):
1974–80.
11. Luo J, Wang T, Gao P, Krings T, Jiao L. Endovascular
treatment of intracranial atherosclerotic stenosis:
current debates and future prospects. Front Neurol.
2018;9:666.
12. Feldmann E, Wilterdink JL, Kosinski A, et al. The
Stroke Outcomes and Neuroimaging of Intracranial
Atherosclerosis (SONIA) Trial. Neurology. 2007;68:
2099–106.
13. Brott TG, Howard G, Roubin GS, et al. Long-term
results of stenting versus endarterectomy for carotid
artery stenosis. N Engl J Med. 2016;374:1021–31.
14. Kumar R, Batchelder A, Saratzis A, et al. Restenosis
after carotid interventions and its relationship with
recurrent ipsilateral stroke: a systematic review and
meta-analysis. Eur J Vasc Endovasc Surg. 2017;53:
766–75.
15. Bonati LH, Gregson J, Dobson J, et al. Restenosis
and risk of stroke after stenting or endarterectomy
for symptomatic carotid stenosis in the Interna-
tional Carotid Stenting Study (ICSS): secondary
analysis of a randomised trial. Lancet Neurol.
2018;17(7):587–96.
16. Mazighi M, Labreuche J, Gongora-Rivera F, Duyck-
aerts C, Hauw JJ, Amarenco P. Autopsy prevalence
of intracranial atherosclerosis in patients with fatal
stroke. Stroke. 2008;39:1142–7.
17. Liebeskind DS, Cotsonis GA, Saver JL, et al. Collat-
erals dramatically alter stroke risk in intracranial
atherosclerosis. Ann Neurol. 2011;69(6):963–74.
18. Kasner SE, Chimowitz MI, Lynn MJ, et al. Predictors
of ischemic stroke in the territory of a symptomatic
intracranial arterial stenosis. Circulation.
2006;113(4):555–63.
19. Gorelick P, Wong KS, Liu L. Epidemiology. In: Kim
JS, Caplan LR, Wong KS, editors. Intracranial
atherosclerosis: pathophysiology, diagnosis and
treatment. Basel: Karger; 2016, vol 40. p. 34–46.
20. Wong KS, Gao S, Chan YL, et al. Mechanisms of
acute cerebral infarctions in patients with middle
cerebral artery stenosis: a diffusion-weighted imag-
ing and microemboli monitoring study. Ann Neu-
rol. 2002;52(1):74–81.
21. Zhu XJ, Wang W, Liu ZJ. High-resolution magnetic
resonance vessel wall imaging for intracranial arte-
rial stenosis. Chin Med J. 2016;129(11):1363–70.
22. Xu WH, Li ML, Gao S, et al. Middle cerebral artery
intraplaque hemorrhage: prevalence and clinical
relevance. Ann Neurol. 2012;71:195–8.
23. Toussaint JF, La Muraglia GM, Southern JF, et al.
Magnetic resonance images lipid, fibrous, calcified,
hemorrhagic, and thrombotic components of
human atherosclerosis in vivo. Circulation.
1996;94(5):932–8.
24. Chung GH, Kwak HS, Hwang SB, et al. High reso-
lution MR imaging in patients with symptomatic
Adv Ther
middle cerebral artery stenosis. Eur J Radiol.
2012;81(12):4069–74.
25. Zacharatos H, Hassan AE, Qureshi AI. Intravascular
ultrasound: principles and cerebrovascular applica-
tions. AJNR Am J Neuroradiol. 2010;31(4):586–97.
26. Chen XY, Wong KS, Lam WW, et al. High signal on
T1 sequence of magnetic resonance imaging con-
firmed to be intraplaque haemorrhage by histology
in middle cerebral artery. Int J Stroke. 2014;9:E19.
27. Van Lammeren GW, et al. Atherosclerotic plaque
biomarkers: beyond the horizon of the vulnerable
plaque. Curr Cardiol Rev. 2011;7:22–7.
28. Sluimer JC, Kolodgie FD, Bijnens AP, et al. Thin-
walled microvessels in human coronary atheroscle-
rotic plaques show incomplete endothelial junc-
tions relevance of compromised structural integrity
for intraplaque microvascular leakage. J Am Coll
Cardiol. 2009;53(17):1517–27.
29. Verhoeven B, Hellings WE, Moll FL, et al. Carotid
atherosclerotic plaques in patients with transient
ischemic attacks and stroke have unstable charac-
teristics compared with plaques in asymptomatic
and amaurosis fugax patients. J Vasc Surg.
2005;42(6):1075–81.
30. Yuan C, Kerwin WS, Ferguson MS, et al. Contrast-
enhanced high resolution MRI for atherosclerotic
carotid artery tissue characterization. J Magn Reson
Imaging. 2002;15:62–7.
31. Caplan LR, Wong KS, Gao S, Hennerici MG. Is
hypoperfusion an important cause of strokes? If so,
how? Cerebrovasc Dis. 2006;21(3):145–53.
32. Kim JS, Nah HW, Park SM, et al. Risk factors and
stroke mechanisms in atherosclerotic stroke:
intracranial compared with extracranial and ante-
rior compared with posterior circulation disease.
Stroke. 2012;43:3313–8.
33. Koo J. The latest information on intracranial
atherosclerosis: diagnosis and treatment. Interv
Neurol. 2015;4:48–50.
34. Feng X, Chan KL, Lan L, et al. Stroke mechanisms in
symptomatic intracranial atherosclerotic disease:
classification and clinical implications. Stroke.
2019;50:2692–9.
35. Caplan LR, Hennerici M. Impaired clearance of
emboli (washout) is an important link between
hypoperfusion, embolism, and ischemic stroke.
Arch Neurol. 1998;55(11):1475–82.
36. Baumgartner RW, Mattle HP, Schroth G. Assess-
ment of[/=50% and\50% intracranial stenoses by
transcranial color-coded duplex sonography.
Stroke. 1999;30(1):87–92.
37. Lo´pez-Cancio E, Dorado L, Milla´n M, et al. The
Barcelona-Asymptomatic Intracranial Atherosclero-
sis (AsIA) study: prevalence and risk factors.
Atherosclerosis. 2012;221(1):221–5.
38. Planas-Ballve´ A, Crespo AM, Aquilar LM, et al. The
Barcelona-Asymptomatic Intracranial Atheroscle-
rotic study: subclinical intracranial atherosclerosis
as predictor of long-term vascular events.
Atherosclerosis. 2019;282:132–6.
39. Bos D, van der Rijk MJ, Geeraedts TE, et al.
Intracranial carotid artery atherosclerosis: preva-
lence and risk factors in the general population.
Stroke. 2012;43(7):1878–84.
40. Nahab F, Cotsonis G, Lynn M, et al. Prevalence and
prognosis of coexistent asymptomatic intracranial
stenosis. Stroke. 2008;39(3):1039–41.
41. Li Y, Cai Y, Zhao M, Sun J. Risk factors between
intracranial-extracranial atherosclerosis and ante-
rior-posterior circulation stroke in ischaemic stroke.
Neurol Res. 2017;39:30–5.
42. Banerjee C, Chimowitz MI. Stroke caused by
atherosclerosis of the major intracranial arteries.
Circ Res. 2017;120:502–13.
43. Lei C, Wu B, Liu M, Chen Y. Risk factors and clinical
outcomes associated with intracranial and
extracranial atherosclerotic stenoses acute ischae-
mic stroke. J Stroke Cerebrovasc Dis. 2014;32:112–7.
44. Holmstedt CA, Turan TN, Chimowitz MI.
Atherosclerotic intracranial arterial stenosis: risk
factors, diagnosis, and treatment. Lancet Neurol.
2013;12(11):1106–14.
45. Chaturvedi S, Turan TN, Lynn MJ, et al. Risk factor
status and vascular events in patients with symp-
tomatic intracranial stenosis. Neurology. 2007;69:
2063–8.
46. Lindhorst J, Alexander N, Blignaut J, Rayner B.
Differences in hypertension between blacks and
whites: an overview. Cardiovasc J Afr. 2007;18(4):
241–7.
47. Alexander RW. Hypertension and the pathogenesis
of atherosclerosis. Oxidative stress and the media-
tion of arterial inflammatory response: a new per-
spective. Hypertension. 1995;25:155–61.
48. Ritz K, Denswil NP, Stam OC, van Lieshout JJ,
Daemen MJ. Cause and mechanisms of intracranial
atherosclerosis. Circulation. 2014;130:1407–14.
Adv Ther
49. Sutton-Tyrrell K, Wolfson SK Jr, Kuller LH. Blood
pressure treatment slows the progression of carotid
stenosis in patients with isolated systolic hyper-
tension. Stroke. 1994;25(1):44–50.
50. Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S,
Chimowitz M, Warfarin-Aspirin Symptomatic
Intracranial Disease (WASID) Trial Investigators.
Relationship between blood pressure and stroke
recurrence in patients with intracranial arterial
stenosis. Circulation. 2007;115:2969–75.
51. Park JH, Ovbiagele B, Hong KS, Kwon SU. Associa-
tion of systolic blood pressure with progression of
symptomatic intracranial atherosclerotic stenosis.
J Stroke. 2017;19(3):304–11.
52. Kwon SU, Hong KS, Kang DW, et al. Efficacy and
safety of combination antiplatelet therapies in
patients with symptomatic intracranial atheroscle-
rotic stenosis. Stroke. 2011;42:2883–90.
53. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stent-
ing versus aggressive medical therapy for intracra-
nial arterial stenosis. N Engl J Med. 2011;365:
993–1003.
54. Turan TN, Nizam A, Lynn M, et al. Relationship
between risk factor control and vascular events in
the SAMMPRIS trial. Neurology. 2017;88(4):379–85.
55. Amin-Hanjani S, Rose-Finnell L, Richardson D, et al.
Vertebrobasilar Flow Evaluation and Risk of Tran-
sient Ischaemic Attack and Stroke study (VERiTAS):
rationale and design. Int J Stroke. 2010;5(6):
499–505.
56. Kernan WN, et al. 2014 AHA/ASA guidelines for the
prevention of stroke in patients with stroke and
transient ischemic attack. A guideline for healthcare
professionals from the American Heart Association/
American Stroke Association. Stroke. 2014;45:
2160–236.
57. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/
EAS guidelines for the management of dyslipi-
daemias: lipid modification to reduce cardiovascu-
lar risk: the Task Force for the management of
dyslipidaemias of the European Society of Cardiol-
ogy (ESC) and European Atherosclerosis Society
(EAS). Eur Heart J. 2020;41(1):111–88.
58. Bae HJ, Lee J, Park JM, et al. Risk factors of
intracranial cerebral atherosclerosis among asymp-
tomatics. Cerebrovasc Dis. 2007;24:355–60.
59. Rincon F, Sacco RL, Kranwinkel G, et al. Incidence
and risk factors of intracranial atherosclerotic
stroke: the Northern Manhattan Stroke Study.
Cerebrovasc Dis. 2009;28:65–71.
60. Katakami N. Mechanism of development of
atherosclerosis and cardiovascular disease in dia-
betes mellitus. J Atheroscler Thromb. 2018;25(1):
27–39.
61. Leung SY, Ng TH, Yuen ST, Lauder IJ, Ho FC. Pattern
of cerebral atherosclerosis in Hong Kong Chinese.
Severity in intracranial and extracranial vessels.
Stroke. 1993;24:779–86.
62. Thomas GN, Lin JW, Lam WW, et al. Increasing
severity of cardiovascular risk factors with increas-
ing middle cerebral artery stenotic involvement in
type 2 diabetic Chinese patients with asymptomatic
cerebrovascular disease. Diabetes Care. 2004;27:
1121–6.
63. Kim YS, Hong JW, Jung WS, et al. Gender differ-
ences in risk factors for intracranial cerebral
atherosclerosis among asymptomatic subjects.
Gend Med. 2011;8:14–22.
64. Matthews DR, Hosker JP, Rudenski AS, Naylor BA,
Treacher DF, Turner RC. Homeostasis model
assessment: insulin resistance and beta-cell func-
tion from fasting plasma glucose and insulin con-
centrations in man. Diabetologia. 1985;28(7):
412–9.
65. Yaghi S, Furie KL, Viscoli CM, et al. Pioglitazone
prevents stroke in patients with a recent transient
ischaemic attack or ischaemic stroke: a planned
secondary analysis of the IRIS Trial (Insulin Resis-
tance Intervention After Stroke). Circulation.
2018;137(5):455–63.
66. Powers WJ, Rabinstein AA, Ackerson T, et al.
Guidelines for the early management of patients
with acute ischaemic stroke: 2019 update to the
2018 guidelines for the early management of acute
ischaemic stroke: a guideline for healthcare profes-
sionals from the American Heart Association/
American Stroke Association. Stroke. 2019;50:
e344–418.
67. Ingall TJ, Homer D, Baker HL Jr, Kottke BA, O’Fallon
WM, Whisnant JP. Predictors of intracranial carotid
artery atherosclerosis. Duration of cigarette smok-
ing and hypertension are more powerful than
serum lipid levels. Arch Neurol. 1991;48:687–91.
68. Heyden S, Heyman A, Goree JA. Nonembolic
occlusion of the middle cerebral and carotid arter-
ies—a comparison of predisposing factors. Stroke.
1970;1:363–9.
69. Wang Y, Meng R, Liu G, et al. Intracranial
atherosclerotic disease. Neurobiol Dis. 2019;124:
118–32.
70. Barth JD, Arntzenius AC. Progression and regression
of atherosclerosis, what roles for LDL-cholesterol
Adv Ther
and HDL-cholesterol: a perspective. Eur Heart J.
1991;12(8):952–7.
71. Weber G. Delayed experimental atherosclerotic
involvement of cerebral arteries in monkeys and
rabbits. Pathol Res Pract. 1985;180:353–5.
72. Inzitari D, Hachinski VC, Taylor DW, Barnett HJ.
Racial differences in the anterior circulation in
cerebrovascular disease: how much can be
explained by risk factors? Arch Neurol. 1990;47:
1080–4.
73. Park JH, Hong KS, Lee EJ, Lee J, Kim DE. High levels
of apolipoprotein B/AI ratio are associated with
intracranial atherosclerotic stenosis. Stroke.
2011;42(11):3040–6.
74. Turan TN, Makki AA, Tsappidi S, et al. Risk factors
associated with severity and location of intracranial
arterial stenosis. Stroke. 2010;41(8):1636–40.
75. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al.
High-dose atorvastatin after stroke or transient
ischaemic attack. N Engl J Med. 2006;10:549–59.
76. Amarenco P, Kim JS, Labreuche J, et al. A compar-
ison of two LDL cholesterol targets after ischemic
stroke. N Engl J Med. 2020;382:9–19.
77. Kernan WN, Inzucchi SE, Sawan C, Macko RF, Furie
KL. Obesity: a stubbornly obvious target for stroke
prevention. Stroke. 2013;44:278–86.
78. Gallanagh S, Quinn TJ, Alexander J, Walters MR.
Physical activity in the prevention and treatment of
stroke. ISRN Neurol. 2011;2011:953818.
79. Turan TN, Kasab SA, Nizam A, et al. Type and
duration of exercise in the SAMMPRIS trial. Neu-
rologist. 2019;24(1):10–2.
80. Piercy KL, Troiano RP, Ballard RM, et al. The phys-
ical activity guidelines for Americans. JAMA.
2018;320(19):2020–8.
81. Ambrose JA, Barua RS. The pathophysiology of
cigarette smoking and cardiovascular disease: an
update. J Am Coll Cardiol. 2004;43(10):1731–7.
82. Ji R, Pan Y, Yan H, et al. Current smoking is asso-
ciated with extracranial carotid atherosclerotic
stenosis but not with intracranial large artery dis-
ease. BMC Neurol. 2017;17(1):120.
83. Kim DE, Lee KB, Jang IM, Roh H, Ahn MY, Lee J.
Associations of cigarette smoking with intracranial
atherosclerosis in the patients with acute ischaemic
stroke. Clin Neurol Neurosurg. 2012;114:1243–7.
84. Miyazawa N, Akiyama I, Yamagata Z. Analysis of
incidence and risk factors for progression in
patients with intracranial steno-occlusive lesions by
serial magnetic resonance angiography. Clin Neurol
Neurosurg. 2007;109:680–5.
85. Chen H, Hong H, Xing S, et al. Intracranial versus
extracranial symptomatic carotid atherosclerosis in
Chinese patients: risk factors, stroke mechanisms,
and long-term prognosis. J Stroke Cerebrovasc Dis.
2015;24:2632–9.
86. Turan TN, Al Kasab S, Nizam A, et al. Relationship
between risk factor control and compliance with a
lifestyle modification program in the Stenting
Aggressive Medical Management for Prevention of
Recurrent Stroke in Intracranial Stenosis Trial.
J Stroke Cerebrovasc Dis. 2018;27(3):801–5.
87. Wang JC, Bennett M. Aging and atherosclerosis.
Circ Res. 2012;111:245–59.
88. Kim JS, Bonovich D. Research on intracranial
atherosclerosis from the east and west: why are the
results different? J Stroke. 2014;16(3):105–13.
89. Forouhi NG, Sattar N. CVD risk factors and ethnic-
ity—a homogeneous relationship? Atheroscler
Suppl. 2006;7:11–9.
90. Chandalia M, Abate N, Garg A, Stray-Gundersen J,
Grundy SM. Relationship between generalized and
upper body obesity to insulin resistance in Asian
Indian men. J Clin Endocrinol Metab. 1999;84:
2329–35.
91. Kuller L, Reisler DM. An explanation for variations
in distribution of stroke and atherosclerotic heart
disease among populations and racial groups. Am J
Epidemiol. 1997;93:1–9.
92. Kim SJ, Moon GJ, Bang OY. Biomarkers for stroke. J
Stroke. 2013;15:27–37.
93. Liao X, Zhang T, Li B, et al. Rare RNF213 variants
and the risk of intracranial artery stenosis/occlusion
disease in Chinese population: a case-control study.
BMC Med Genet. 2019;20(1):55.
94. Genton E, Barnett HJ, Fields WS, Gent M, Hoak JC.
Cerebral ischemia: the role of thrombosis and of
antithrombotic therapy. Study group on
antithrombotic therapy. Stroke. 1977;8:150–75.
95. Alberts MJ, Bergman DL, Molner E, Jovanovic BD,
Ushiwata I, Teruya J. Antiplatelet effect of aspirin in
patients with cerebrovascular disease. Stroke.
2004;35:175–8.
96. Helgason CM, Bolin KM, Hoff JA, et al. Develop-
ment of aspirin resistance in persons with previous
ischaemic stroke. Stroke. 1994;25:2331–6.
Adv Ther
97. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs
IB. High-dose aspirin inhibits shear-induced platelet
reaction involving thrombin generation. Circula-
tion. 1992;85:1077–82.
98. Ridker PM, Cushman M, Stampfer MJ, Tracy RP,
Hennekens CH. Inflammation, aspirin, and the risk
of cardiovascular disease in apparently healthy
men. N Engl J Med. 1997;336:973–9.
99. Kharbanda RK, Walton B, Allen M, et al. Prevention
of inflammation-induced endothelial dysfunction:
a novel vasculo-protective action of aspirin. Circu-
lation. 2002;105:2600–4.
100. Khan A, Kasner SE, Lynn MJ, Chimowitz MI, War-
farin Aspirin Symptomatic Intracranial Disease
(WASID) Trial Investigators. Risk factors and out-
come of patients with symptomatic intracranial
stenosis presenting with lacunar stroke. Stroke.
2012;43(5):1230–3.
101. Kasner SE, Lynn MJ, Chimowitz MI, et al. Warfarin
vs aspirin for symptomatic intracranial stenosis:
subgroup analyses from WASID. Neurology.
2006;67(7):1275–8.
102. Lip GYH, Keshishian A, Li X, et al. Effectiveness and
safety of oral anticoagulants among nonvalvular
atrial fibrillation patients. Stroke. 2018;49:2933–44.
103. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban
versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med. 2011;365(10):883–91.
104. Patel P, Pandya J, Goldberg M. NOACs vs. warfarin
for stroke prevention in nonvalvular atrial fibrilla-
tion. Cureus. 2017;9:1395.
105. Xue Z, Zhang H. Non-vitamin K antagonist oral
anticoagulants versus warfarin in Asians with atrial
fibrillation: meta-analysis of randomized trials and
real-world studies. Stroke. 2019;50:2819–28.
106. Wong KS, Chen C, Fu J, et al. Clopidogrel plus
aspirin versus aspirin alone for reducing embolisa-
tion in patients with acute symptomatic cerebral or
carotid artery stenosis (CLAIR study): a randomised,
open-label, blinded-endpoint trial. Lancet Neurol.
2010;9:489–97.
107. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with
aspirin in acute minor stroke or transient ischemic
attack. N Engl J Med. 2013;369(1):11–9.
108. Liu L, Wong KS, Leng X, et al. Dual antiplatelet
therapy in stroke and ICAS: subgroup analysis of
CHANCE. Neurology. 2015;85(13):1154–62.
109. Zaidat OO, Fitzsimmons BF, Woodward BK, et al.
Effect of a balloon-expandable intracranial stent vs
medical therapy on risk of stroke in patients with
symptomatic intracranial stenosis: the VISSIT ran-
domized clinical trial. JAMA. 2015;313:1240–8.
110. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents
the progression of the symptomatic intracranial
arterial stenosis: the multicenter double-blind pla-
cebo-controlled trial of cilostazol in symptomatic
intracranial arterial stenosis. Stroke. 2005;36:782–6.
111. Johnston SC, Amarenco P, Albers GW, et al. Tica-
grelor versus aspirin in acute stroke or transient
ischaemic attack. N Engl J Med. 2016;375:35–43.
112. Amarenco P, Albers GW, Denison H, et al. Efficacy
and safety of ticagrelor versus aspirin in acute stroke
or transient ischaemic attack of atherosclerotic ori-
gin: a subgroup analysis of SOCRATES, a ran-
domised, double-blind controlled trial. Lancet
Neurol. 2017;16:301–10.
113. Ogawa A, Toyoda K, Kitagawa K, et al. Comparison
of prasugrel and clopidogrel in patients with non-
cardioembolic ischaemic stroke: a phase 3, ran-
domised, non-inferiority trial (PRASTRO-I). Lancet
Neurol. 2019;18(3):238–47.
114. Fiorella D. Endovascular treatment of intracranial
stenosis. World Neurosurg. 2011;76(6):66–70.
115. Sundt TM, Smith HC, Campbell JK, et al. Translu-
minal angioplasty for basilar artery stenosis. Mayo
Clin Proc. 1980;55:673–80.
116. Connors JJ, Wojak JC. Percutaneous transluminal
angioplasty for intracranial atherosclerotic lesions:
evolution of technique and short-term results.
J Neurosurg. 1999;91:415–23.
117. Feldman RL, Trigg L, Gaudier J, et al. Use of coro-
nary Palmaz-Schatz stent in the percutaneous
treatment of an intracranial carotid artery stenosis.
Cathet Cardiovasc Diagn. 1996;38:316–9.
118. Rasmussen PA, Perl J, Barr JD, et al. Stent-assisted
angioplasty of intracranial vertebrobasilar
atherosclerosis: an initial experience. J Neurosurg.
2000;92:771–8.
119. Marks MP, Wojak JC, Al-Ali F, et al. Angioplasty for
symptomatic intracranial stenosis: clinical out-
come. Stroke. 2006;37:1016–20.
120. SSYLVIA Study Investigators. Stenting of symp-
tomatic atherosclerotic lesions in the vertebral or
intracranial arteries (SSYLVIA): study results. Stroke.
2004;35:1388–92.
121. Derdeyn CP, Chimowitz MI, Lynn MJ, et al.
Aggressive medical treatment with or without
stenting in high-risk patients with intracranial
artery stenosis (SAMMPRIS): the final results of a
randomised trial. Lancet. 2014;383:331–41.
Adv Ther
122. Bose A, Hartmann M, Henkes H, et al. A novel, self-
expanding, nitinol stent in medically refractory
intracranial atherosclerotic stenoses: the Wingspan
study. Stroke. 2007;38:1531–7.
123. Amin-Hanjani S, Stapleton CJ, Du X, et al. Hypop-
erfusion symptoms poorly predict hemodynamic
compromise and stroke risk in vertebrobasilar dis-
ease. Stroke. 2019;50(2):495–7.
124. Lutsep HL, Lynn MJ, Cotsonis GA, et al. Does
SAMMPRIS support stenting over medical therapy
for subpopulations of patients with intracranial
arterial stenosis? Stroke. 2015;46(11):3282–4.
125. Fiorella D, Derdeyn CP, Lynn MJ, et al. Detailed
analysis of periprocedural strokes in patients
undergoing intracranial stenting in stenting and
aggressive medical management for preventing
recurrent stroke in intracranial stenosis (SAMM-
PRIS). Stroke. 2012;43:2682–8.
126. Abou-Chebl A, Steinmetz H. Critique of ‘‘Stenting
versus aggressive medical therapy for intracranial
arterial stenosis’’ by Chimowitz et al in the New
England Journal of Medicine. Stroke. 2012;43:
616–20.
127. Gro¨schel K, Schnaudigel S, Pilgram SM, Wasser K,
Kastrup A. A systematic review on outcome after
stenting for intracranial atherosclerosis. Stroke.
2009;40:e340.
128. Markus HS, Larsson SC, Kuker W, et al. Stenting for
symptomatic vertebral artery stenosis. Neurology.
2017;89:1229–36.
129. Compter A, van der Worp HB, Schonewille WJ, et al.
Stenting versus medical treatment in patients with
symptomatic vertebral artery stenosis: a randomised
open-label phase 2 trial. Lancet Neurol. 2015;14(6):
606–14.
130. Alexander MJ, Zauner A, Chaloupka JC, et al.
WEAVE trial: final results in 152 on-label patients.
Stroke. 2019;50(4):889–94.
131. Gao P, Zhao Z, Wang D, et al. China Angioplasty
and Stenting for Symptomatic Intracranial Severe
Stenosis (CASSISS): a new, prospective, multicenter,
randomized controlled trial in China. Interv Neu-
roradiol. 2015;2:196–204.
132. Mori T, Fukuoka M, Kazita K, Mori K. Follow-up
study after intracranial percutaneous transluminal
cerebral balloon angioplasty. AJNR Am J Neurora-
diol. 1998;19(8):1525–33.
133. Miao Z, Song L, Liebeskind DS, et al. Outcomes of
tailored angioplasty and/or stenting for symp-
tomatic intracranial atherosclerosis: a prospective
cohort study after SAMMPRIS. J Neurointerv Surg.
2015;7(5):331–5.
134. Kang DH, Yoon W. Current opinion on endovas-
cular therapy for emergent large vessel occlusion
due to underlying intracranial atherosclerotic
stenosis. Korean J Radiol. 2019;20:739–48.
135. Park H, Baek JH, Kim BM. Endovascular treatment
of acute stroke due to intracranial atherosclerotic
stenosis-related large vessel occlusion. Front Neurol.
2019;2(10):308.
136. Lee JS, Hong JM, Lee KS, et al. Endovascular therapy
of cerebral arterial occlusions: intracranial
atherosclerosis versus embolism. J Stroke Cere-
brovasc Dis. 2015;24:2074–80.
137. Kim BM. Causes and solutions of endovascular
treatment failure. J Stroke. 2017;19:131–42.
138. Kawashima M, Rhoton AL Jr, Tanriover N, Ulm AJ,
Yasuda A, Fujii K. Microsurgical anatomy of cerebral
revascularization. Part I: anterior circulation. J Neu-
rosurg. 2005;102:116–31.
139. EC/IC Bypass Study Group. Failure of extracranial-
intracranial arterial bypass to reduce the risk of
ischaemic stroke. Results of an international ran-
domized trial. N Engl J Med. 1985;313:1191–200.
140. Awad IA, Spetzler RF. Extracranial-intracranial
bypass surgery: a critical analysis in light of the
international cooperative study. Neurosurgery.
1986;19:655–64.
141. Ausman JI, Diaz FG. Critique of the extracranial-
intracranial bypass study. Surg Neurol. 1986;26(3):
218–21.
142. Low SW, Teo K, Lwin S, et al. Improvement in
cerebral hemodynamic parameters and outcomes
after superficial temporal artery-middle cerebral
artery bypass in patients with severe steno occlusive
disease of the intracranial internal carotid or middle
cerebral arteries. J Neurosurg. 2015;123(3):662–9.
Adv Ther
